Your browser doesn't support javascript.
loading
Role of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration.
Brunetti, Dario; Catania, Alessia; Viscomi, Carlo; Deleidi, Michela; Bindoff, Laurence A; Ghezzi, Daniele; Zeviani, Massimo.
Afiliação
  • Brunetti D; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy.
  • Catania A; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20126 Milan, Italy.
  • Viscomi C; Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20126 Milan, Italy.
  • Deleidi M; Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy.
  • Bindoff LA; German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany.
  • Ghezzi D; Neuro-SysMed, Center of Excellence for Clinical Research in Neurological Diseases, Haukeland University Hospital, N-5021 Bergen, Norway.
  • Zeviani M; Department of Clinical Medicine, University of Bergen, N-5021 Bergen, Norway.
Biomedicines ; 9(7)2021 Jul 17.
Article em En | MEDLINE | ID: mdl-34356897
ABSTRACT
Mounting evidence shows a link between mitochondrial dysfunction and neurodegenerative disorders, including Alzheimer Disease. Increased oxidative stress, defective mitodynamics, and impaired oxidative phosphorylation leading to decreased ATP production, can determine synaptic dysfunction, apoptosis, and neurodegeneration. Furthermore, mitochondrial proteostasis and the protease-mediated quality control system, carrying out degradation of potentially toxic peptides and misfolded or damaged proteins inside mitochondria, are emerging as potential pathogenetic mechanisms. The enzyme pitrilysin metallopeptidase 1 (PITRM1) is a key player in these processes; it is responsible for degrading mitochondrial targeting sequences that are cleaved off from the imported precursor proteins and for digesting a mitochondrial fraction of amyloid beta (Aß). In this review, we present current evidence obtained from patients with PITRM1 mutations, as well as the different cellular and animal models of PITRM1 deficiency, which points toward PITRM1 as a possible driving factor of several neurodegenerative conditions. Finally, we point out the prospect of new diagnostic and therapeutic approaches.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article